In line / mixed
Organic growth reached about 18%, with FARAPULSE providing roughly half and the rest of the portfolio still growing near double digits.
[AS-EXP-025]Boston Scientific
Q3 2024: A broad beat-and-raise was temporarily obscured by a clinical-trial pause unrelated to commercial demand.
ResultIn line / mixedGuidanceMixed / newly framedEnvironmentimproving
Investment snapshot
What happened and why it mattered
Mixed / newly framed
The full-year organic-sales increase exceeded the dollar value of the quarterly beat, signaling confidence in the exit rate.
[AS-EXP-025]No clear inflection
The full-year organic-sales increase exceeded the dollar value of the quarterly beat, signaling confidence in the exit rate.
[AS-EXP-025]Qualitative
The same-day reaction centered on the AVANT GUARD pause, which faded after enrollment resumed.
[AS-ME-081]Results versus expectations
The print and the three most important read-throughs
Organic growth reached about 18%, with FARAPULSE providing roughly half and the rest of the portfolio still growing near double digits.
- 1
Organic growth reached about 18%, with FARAPULSE providing roughly half and the rest of the portfolio still growing near double digits.
Guidance bridge
GuidanceMixed / newly framedLatest outlook and KPI implications
The full-year organic-sales increase exceeded the dollar value of the quarterly beat, signaling confidence in the exit rate.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY2024 reported sales growth | 13.5–14.5% | ~16.5% | ~14.5% | Raised ~200bps at midpoint | Raised | Portfolio momentum, AF solutions; +200bps M&A contribution, ~50bps FX headwind |
| FY2024 organic sales growth | 13–14% | ~15% | ~13.9% (Street) | Raised ~150bps at midpoint | Raised | Broad portfolio, particularly EP/FARAPULSE |
| FY2024 adjusted EPS | $2.38–$2.42 | $2.45–$2.47 | $2.41 (Street) | Raised $0.05 at midpoint (+20–21% Y/Y) | Raised | Strong sales performance; unchanged $0.04 FX headwind |
| Q4 2024 reported sales growth | Not previously issued | 16.5–18.5% | ~14.8% reported (Street) | New | New | ~50bps FX tailwind, +200bps M&A |
| Q4 2024 organic sales growth | Not previously issued | 14–16% | ~13.5% (Street) | New | New | Momentum in AF solutions |
| Q4 2024 adjusted EPS | Not previously issued | $0.64–$0.66 | $0.64 (consensus) | New | New | Sales drop-through |
Management signal — paraphrased
The full-year organic-sales increase exceeded the dollar value of the quarterly beat, signaling confidence in the exit rate.
Implied cadence
The full-year organic-sales increase exceeded the dollar value of the quarterly beat, signaling confidence in the exit rate.
Stock reaction
Why the shares moved
The same-day reaction centered on the AVANT GUARD pause, which faded after enrollment resumed.
- The same-day reaction centered on the AVANT GUARD pause, which faded after enrollment resumed.
Did the reaction persist?
[AS-ME-081]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentimprovingWhat management said about the operating backdrop
A broad beat-and-raise was temporarily obscured by a clinical-trial pause unrelated to commercial demand.
- Customer demand / procedure volumesMixed
Summer slowdown in July–August in endo/uro, "nice procedure bounce back in September"
OutlookVolumes expected to remain strongKPI implicationSupports ~7–8% MedSurg organic growthManagement interpretation · Medium confidence · [133] - Volumes / order activity (EP)Improving
EP grew "an exceptional 177%" driven by increased AF ablation volumes
OutlookContinued underpenetrated AF ablation TAMKPI implicationEP the single largest driver of ~$100M top-line beatDisclosed fact · High confidence · [134] - Regional / China / APAC / EMStable
APAC +12.3%; US +23.5%; EMEA +14.3%; emerging markets +16.8%
OutlookChina/Japan FARAPULSE launches rampingKPI implicationBroad-based geographic contribution to 18.2% organicBroker/peer evidence · High confidence · [137]
- Channel / inventory (POLARx, capital placements)Improving (inventory) / Stable (capital)
No comparable incremental charge; capital placements "remained elevated" 6–7 months into launch
OutlookSingle-use catheter mix to accelerate in 2025KPI implicationRemoves a Q2-style GM drag; capital still dilutive at the edgesBroker/peer evidence · Medium confidence · [135] - Supply availabilityImproving
"We don't anticipate any supply shortages" despite high demand
OutlookAbsorption improves as volumes rampKPI implicationSupports sustained FARAPULSE revenue conversionManagement interpretation · Medium confidence · [136] - Input costs / FX / manufacturingImproving
Only 10bps FX headwind, "favorable versus our expectations"
Outlook2H manufacturing investment continuesKPI implicationGM of 70.4% "slightly lower than anticipated, driven primarily by FX"Disclosed fact · High confidence · [128]
- Competition (Affera/MDT, Varipulse/JNJ)Stable
Competitors' first-gen products "not materially impact[ed] the rapid sustained adoption of FARAPULSE in Europe"
OutlookUS entrants late 2024/early 2025; BSX to defend leadershipKPI implicationBSX assumed ~60% PFA share exiting 2024 per BofAManagement interpretation · Medium confidence · [131] - Pricing (China VBP)Worsening (pricing) / Stable (growth)
Grew "essentially at the company average in China despite those headwinds"; more VBPs expected in 2025
OutlookAdditional VBP pressure on IVUS in 2025KPI implicationContains China (~$1B sales) growth despite price cutsManagement interpretation · Medium confidence · [132]
Evidence and confidence
Source map
No material gap recorded.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗